
Zhen Su/LinkedIn
May 4, 2025, 06:11
Zhen Su: The era of Immun-oncology 2.0 is here
Zhen Su, CEO at Marengo Therapeutics, shared a post on LinkedIn:
“We are truly grateful for the opportunity to share our recent learnings from Phase 1/2 clinical investigation of Invikafusp Alfa as monotherapy to overcome PD-1 resistant cancer as a clinical plenary oral presentation at the Annual AACR conference in Chicago!
A stellar presentation by Dr. Ryan Sullivan and superb discussion by Dr. Jason Luke! A sincere thank you to all the investigators and patients who trusted us with this journey to advance the next wave of cancer immunotherapy.
The era of IO 2.0 is here!”
More posts featuring AACR 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 4, 2025, 06:11
May 4, 2025, 05:16
May 4, 2025, 05:00
May 4, 2025, 04:45
May 4, 2025, 02:53